<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656809</url>
  </required_header>
  <id_info>
    <org_study_id>14-01459</org_study_id>
    <nct_id>NCT03656809</nct_id>
  </id_info>
  <brief_title>Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer</brief_title>
  <official_title>Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of routine referral to genetic
      counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or
      fallopian tube cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of timely routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or Fallopian tube cancer.</measure>
    <time_frame>9 Months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">125</enrollment>
  <condition>Ovarian Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      multi-gene panel testing
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        new diagnosis of epithelial ovarian, primary peritoneal, fallopian tube or extra- uterine
        mullerian cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must have a new diagnosis of epithelial ovarian, primary peritoneal,
             fallopian tube or extra- uterine mullerian cancer.

          -  All subjects must have either undergone primary surgery or be planning neoadjuvant
             chemotherapy for the treatment of ovarian, primary peritoneal or fallopian tube
             cancer.

          -  All subjects must be able to comprehend and communicate in English.

          -  All subjects must agree to participate.

          -  A previous diagnosis of cancer is not an exclusion criterion.

          -  Previous genetic screening is not an exclusion criterion.

        Exclusion Criteria:

          -  Patients who do not meet the above inclusion criteria.

          -  Patients with a diagnosis of a low malignant potential mullerian tumor.

          -  Patients who are not proficient in English language because the survey aspect of this
             study is comprised of 4 validated surveys that are only available in English language.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Levine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

